🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Abstract #245 Mutter et al, Inferred Gene Expression By Cell-Free DNA Profiling Allows Noninvasive Lymphoma Classification #EPIC-Seq #DoubleHit #DZSig #MachineLearning Jurik Mutter Joe Schroers-Martin, MD Mohammad Shahrokh Esfahani Max Diehn, MD/PhD sciencedirect.com/science/articl… ash.confex.com/ash/2023/webpr…

Abstract #528 Schroers-Martin et al, Longitudinal Noninvasive Surveillance & Fragmentomic Characterization of Follicular Lymphoma #FL #PhasED-Seq #CAPP-Seq #EPIC-Seq #ctDNA #transformation Joe Schroers-Martin, MD Max Diehn, MD/PhD sciencedirect.com/science/articl… ash.confex.com/ash/2023/webpr…

This is a really important analysis in an area of a BIG unmet need (ie, biology in older #HL pts, etc). Surprised this is not an oral presentation. Interesting findings re: EBV and ctDNA. Look forward to the poster & ultimate manuscript. #ASH23 #ASHKudos #GeriOnc #GeriHem

⁦Joe Schroers-Martin, MD⁩ rocking the podium at #ASH23 with his multimodal studies of #FL #ctDNA including transformation

Luttwak et al Adverse impact of POD24 in FL is driven by high grade transformation Risk factors for early transformation include: ⬆️SUVmax ⬆️bulk effusions ⬆️LDH Spleen involved Exclude occult HT in these #lymsm #ASH23

I have had some amazing mentors, sponsors, and role models in my life and am so grateful for each of them. Big thank you to Amylou Dueck, PhD for being a wonderful part of my life and mentoring and supporting me. She taught Amber Koehler, PA-C Côme Bommier and me so much about PROs! #ASH23

Thrilled to share our new study describing distinct subtypes of #HodgkinLymphoma #cHL out today nature. #lymsm 1/15 nature.com/articles/s4158… PDF link at bottom of this thread

Impressive data from our first year fellow Evelyn Orlando showing the impact of preemptive rituximab in prevention of PTLD in solid organ transplant recipients. Very large sample! Jennifer Amengual

Very excited to share our new study measuring clinical specificity of #immunoglobulin based high-throughput sequencing #IgHTS for #MRD measurement in mature B-cell #lymphomas. #lymsm ashpublications.org/bloodadvances/…

We're back with more #organoids! A team at Stanford University and UC Irvine generated patient-derived #lymphoma organoids to study the tumor microenvironment. Jenna Kastenschmidt Joe Schroers-Martin, MD @lisa_wagar Ash Alizadeh, MD/PhD 🇺🇸 🔖 Cell Stem Cell: bit.ly/3SUQXkr 💬: bit.ly/3P86zzP

Excited to share our work on bispecific immunotherapy modeling with #lymphoma #organoids

Monumental effort by GLOW team in publishing the largest analysis of NLPHL to date and answering many key questions about age specific risks, the prognostic impact of variant patterns, and developing a new LP-IPS: ascopubs.org/doi/10.1200/JC… GLOW: Global nLPHL One Working Group Journal of Clinical Oncology Jamie Flerlage

A call to solid organ transplant centers! Does anyone have banked plasma samples from transplant patients who have subsequently developed PTLD (pre-diagnosis samples)? Please LMK- we’d love to collaborate for an NIH grant! Ash Alizadeh, MD/PhD 🇺🇸 Joe Schroers-Martin, MD The ISHLT American Journal of Transplantation

Wow, what? A picture is worth 1000, etc.

Looking forward to speaking on #ctDNA in lymphoma at the Lymphoma, Leukemia & Myeloma Congress #llmcongress2024 next week!

Interim PET/CT based strategies have allowed personalized treatment of classic Hodgkin lymphoma. What are the next steps for response adapted therapy in the era of immunotherapies and ctDNA? A review of novel agent approaches and emerging technologies. sciencedirect.com/science/articl…

Excited to discuss cell-free DNA in post-transplant lymphomas in the Sunday session on the lymphoma TME and immunology, an ongoing multicenter collaboration with Ash Alizadeh, MD/PhD 🇺🇸 Kiran Khush : ash.confex.com/ash/2024/webpr…

At a full capacity #ASH24 session on "Moving the Needle in Hodgkin Lymphoma" - please take a look at our education chapter on the current role of BV! ashpublications.org/hematology/art…

Boegeholz - Biology of older cHL - >60y have lower mutationsl burden, more H2 - 15% have Bcl2-IgH translocation, poor prog - More likely EBV+ - subgroup with multiple viruses, ?immunosupp background - Risk score: Bcl2-IgH, EBV & high CtDNA Fantastic work! #ASH24 #lymsm